Updated Jul 16, 2026
Hollywood Mark has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $139K.

Mark Hollywood is listed in SEC filing CIK 0002104446 as EVP and Chief Operating Officer of Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics including zanidatamab. The filing dated 2026-01-13 reports no insider purchases or sales by Hollywood and identifies him in Zymeworks' executive leadership.
| Role | EVP & Chief Operating Officer |
|---|---|
| Notability | 40/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-06 | ZYME | Zymeworks Inc. | A — Grant or award | 939 | $22.22 | $21K |
| 2026-01-13 | ZYME | Zymeworks Inc. | S — Open-market sale | 6.1K | $22.67 | $139K |
| 2026-01-13 | ZYME | Zymeworks Inc. | M — Option exercise | 17.7K | $0.00 |
Mark Hollywood is listed in SEC filing CIK 0002104446 as EVP and Chief Operating Officer of Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics including zanidatamab. The filing dated 2026-01-13 reports no insider purchases or sales by Hollywood and identifies him in Zymeworks' executive leadership.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($139K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Hollywood Mark profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.